KENNETH R HESS to Humans
This is a "connection" page, showing publications KENNETH R HESS has written about Humans.
Connection Strength
0.696
-
Beneficial Effect of Adjuvant Dabrafenib Plus Trametinib on Recurrence-Free Survival in Patients With Resected BRAFV600-Mutant Stage III Melanoma Seems to be Short-Lived. J Clin Oncol. 2019 05 20; 37(15):1354-1355.
Score: 0.014
-
Clinical importance of eflornithine (a-difluoromethylornithine) for the treatment of malignant gliomas. CNS Oncol. 2018 04; 7(2):CNS16.
Score: 0.012
-
New option for the initial management of metastatic pancreatic cancer? J Clin Oncol. 2014 Aug 10; 32(23):2405-7.
Score: 0.010
-
Getting more out of survival data by using the hazard function. Clin Cancer Res. 2014 Mar 15; 20(6):1404-9.
Score: 0.009
-
Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer. J Natl Compr Canc Netw. 2014 Feb; 12(2):194-203.
Score: 0.009
-
Effect of HER2 status on distant recurrence in early stage breast cancer. Breast Cancer Res Treat. 2013 Jan; 137(2):449-55.
Score: 0.009
-
Glioblastoma resection. J Neurosurg. 2012 May; 116(5):1166-7; author reply 1167-8.
Score: 0.008
-
Lack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems. BMC Bioinformatics. 2011 Dec 01; 12:463.
Score: 0.008
-
Comparing survival curves using an easy to interpret statistic. Clin Cancer Res. 2010 Oct 15; 16(20):4912-3.
Score: 0.007
-
Learning curves in classification with microarray data. Semin Oncol. 2010 Feb; 37(1):65-8.
Score: 0.007
-
Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer. Clin Cancer Res. 2007 Oct 15; 13(20):6080-6.
Score: 0.006
-
Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas. BMC Cancer. 2007 Jun 22; 7:106.
Score: 0.006
-
Statistical issues in clinical trial design. Curr Oncol Rep. 2007 Jan; 9(1):55-9.
Score: 0.006
-
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006 Sep 10; 24(26):4236-44.
Score: 0.006
-
Metastatic patterns in adenocarcinoma. Cancer. 2006 Apr 01; 106(7):1624-33.
Score: 0.005
-
Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme. J Neurooncol. 2006 May; 78(1):85-90.
Score: 0.005
-
Clinical trial design for microarray predictive marker discovery and assessment. Ann Oncol. 2004 Dec; 15(12):1731-7.
Score: 0.005
-
Adult glioma incidence trends in the United States, 1977-2000. Cancer. 2004 Nov 15; 101(10):2293-9.
Score: 0.005
-
Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro Oncol. 2003 04; 5(2):89-95.
Score: 0.004
-
Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat. 2003 Mar; 78(1):105-18.
Score: 0.004
-
Combination Therapy of Physical Activity and Dexamethasone for Cancer-Related Fatigue: A Phase II Randomized Double-Blind Controlled Trial. J Natl Compr Canc Netw. 2021 12 29; 20(3):235-243.
Score: 0.004
-
Microarrays: handling the deluge of data and extracting reliable information. Trends Biotechnol. 2001 Nov; 19(11):463-8.
Score: 0.004
-
Statistical pattern analysis of gene expression profiles for glioblastoma tissues and cell lines. Int J Mol Med. 2001 Aug; 8(2):183-8.
Score: 0.004
-
Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design. J Clin Oncol. 2001 Aug 01; 19(15):3445-6.
Score: 0.004
-
"Ditzels" on chest CT: survey of members of the Society of Thoracic Radiology. AJR Am J Roentgenol. 2001 Jun; 176(6):1363-9.
Score: 0.004
-
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Ann Surg. 2000 Nov; 232(5):727.
Score: 0.004
-
Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res. 2000 Oct; 6(10):3878-84.
Score: 0.004
-
Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Res Treat. 2021 Jan; 185(1):1-12.
Score: 0.004
-
Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC. J Thorac Oncol. 2020 12; 15(12):1919-1927.
Score: 0.004
-
Central nervous system miliary metastasis in breast cancer: a case series analysis and proposed identification criteria of a rare metastasis subtype. Br J Cancer. 2020 10; 123(9):1417-1423.
Score: 0.004
-
Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. BMC Cancer. 2020 May 18; 20(1):430.
Score: 0.004
-
Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors. J Immunother Cancer. 2020 04; 8(1).
Score: 0.004
-
Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1).
Score: 0.004
-
The role of magnetic resonance imaging in patients with palpable breast abnormalities and negative mammographic and sonographic findings. Breast J. 2020 07; 26(7):1289-1295.
Score: 0.004
-
Sleep disturbance in patients with cancer: a feasibility study of multimodal therapy. BMJ Support Palliat Care. 2021 Jun; 11(2):170-179.
Score: 0.004
-
Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Pancreatology. 2020 Apr; 20(3):501-504.
Score: 0.004
-
Imaging Features of Triple Negative Breast Cancer and the Effect of BRCA Mutations. Curr Probl Diagn Radiol. 2021 May-Jun; 50(3):303-307.
Score: 0.004
-
Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clin Cancer Res. 2020 04 15; 26(8):1924-1931.
Score: 0.004
-
Hazard function estimators: a simulation study. Stat Med. 1999 Nov 30; 18(22):3075-88.
Score: 0.004
-
Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res. 1999 Nov; 5(11):3403-10.
Score: 0.004
-
Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. JAMA Oncol. 2019 11 01; 5(11):1597-1604.
Score: 0.004
-
Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res. 2019 12; 7(12):1903-1909.
Score: 0.004
-
Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer. J Thorac Oncol. 2020 02; 15(2):266-273.
Score: 0.004
-
Response and progression in recurrent malignant glioma. Neuro Oncol. 1999 10; 1(4):282-8.
Score: 0.004
-
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol. 2020 02 10; 38(5):388-394.
Score: 0.003
-
Variation in Technical Quality of Breast MRI. Acad Radiol. 2020 04; 27(4):468-475.
Score: 0.003
-
Imaging Follow-up Versus Surgical Excision for Radial Scars Identified on Tomosynthesis-Guided Core Needle Biopsy. Acad Radiol. 2020 03; 27(3):389-394.
Score: 0.003
-
Somatotopy and Organization of Spinothalamic Tracts in the Human Cervical Spinal Cord. Neurosurgery. 2019 06 01; 84(6):E311-E317.
Score: 0.003
-
Risk of Distant Metastasis in Parathyroid Carcinoma and Its Effect on Survival: A Retrospective Review from a High-Volume Center. Ann Surg Oncol. 2019 Oct; 26(11):3593-3599.
Score: 0.003
-
Not all patients with a diagnosis of a radial scar require excision. Breast J. 2019 07; 25(4):792-794.
Score: 0.003
-
Immediate Migration of Biopsy Clip Markers After Upright Digital Breast Tomosynthesis-Guided Vacuum-Assisted Core Biopsy. Acad Radiol. 2020 02; 27(2):204-209.
Score: 0.003
-
Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol. 1999 May; 42(3):227-31.
Score: 0.003
-
Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1). Breast Cancer Res Treat. 2019 Jul; 176(1):227-234.
Score: 0.003
-
Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. J Med Internet Res. 2019 03 14; 21(3):e10348.
Score: 0.003
-
Minimally Invasive Cordotomy for Refractory Cancer Pain: A Randomized Controlled Trial. Oncologist. 2019 07; 24(7):e590-e596.
Score: 0.003
-
Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. Invest New Drugs. 2019 04; 37(2):345-351.
Score: 0.003
-
Moving Precision Oncology Forward Amid Myths and Misconceptions. JAMA Oncol. 2018 12 01; 4(12):1788-1789.
Score: 0.003
-
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. Cancer. 2019 02 01; 125(3):424-433.
Score: 0.003
-
Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. Clin Cancer Res. 2018 12 15; 24(24):6594-6610.
Score: 0.003
-
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist. 2018 11; 23(11):1300-1309.
Score: 0.003
-
Sex as a predictor of response to cancer immunotherapy. Lancet Oncol. 2018 08; 19(8):e376.
Score: 0.003
-
Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clin Breast Cancer. 2018 12; 18(6):e1283-e1288.
Score: 0.003
-
High risk breast lesions identified on MRI-guided vacuum-assisted?needle?biopsy: outcome of surgical excision and imaging follow-up. Br J Radiol. 2018 Oct; 91(1090):20180300.
Score: 0.003
-
Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. J Immunother. 2018 Jul/Aug; 41(6):284-291.
Score: 0.003
-
An effort expenditure perspective on cancer-related fatigue. Psychoneuroendocrinology. 2018 10; 96:109-117.
Score: 0.003
-
Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res. 2018 09 15; 24(18):4416-4428.
Score: 0.003
-
Imaging of Intracystic Papillary Carcinoma. Curr Probl Diagn Radiol. 2019 Jul - Aug; 48(4):348-352.
Score: 0.003
-
Comparison of Residual Risk-Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies. JAMA Oncol. 2018 Apr 12; 4(4):e175092.
Score: 0.003
-
Survival prediction tools for esophageal and gastroesophageal junction cancer: A systematic review. J Thorac Cardiovasc Surg. 2018 08; 156(2):847-856.
Score: 0.003
-
Assessing response to chemotherapy in malignant glioma: the role of steroids. Neurology. 1998 Apr; 50(4):1197; disscussion 1197-8.
Score: 0.003
-
Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer. 2018 06 01; 124(11):2299-2305.
Score: 0.003
-
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 03; 19(3):310-322.
Score: 0.003
-
Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. Thyroid. 2018 01; 28(1):79-87.
Score: 0.003
-
Volumetric response of progressing post-SRS lesions treated with laser interstitial thermal therapy. J Neurooncol. 2018 Mar; 137(1):57-65.
Score: 0.003
-
Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2253-61.
Score: 0.003
-
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs. 2018 08; 36(4):638-646.
Score: 0.003
-
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Invest New Drugs. 2018 08; 36(4):601-607.
Score: 0.003
-
TIE2 Associates with Caveolae and Regulates Caveolin-1 To Promote Their Nuclear Translocation. Mol Cell Biol. 2017 Nov 01; 37(21).
Score: 0.003
-
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 Nov; 67(6):472-492.
Score: 0.003
-
Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors. J Natl Cancer Inst. 2017 10 01; 109(10).
Score: 0.003
-
Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiother Oncol. 2017 10; 125(1):80-88.
Score: 0.003
-
A Double-Blind, Randomized, Placebo-Controlled Trial of Panax Ginseng for Cancer-Related Fatigue in Patients With Advanced Cancer. J Natl Compr Canc Netw. 2017 09; 15(9):1111-1120.
Score: 0.003
-
Patterns of metastatic progression after definitive radiation therapy for early-stage and locally advanced non-small cell lung cancer. Clin Exp Metastasis. 2017 06; 34(5):315-322.
Score: 0.003
-
Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemother Pharmacol. 2017 Sep; 80(3):583-589.
Score: 0.003
-
Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017 08; 18(8):1040-1048.
Score: 0.003
-
Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma. Neuro Oncol. 2017 06 01; 19(6):786-795.
Score: 0.003
-
Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival. Neuro Oncol. 2017 05 01; 19(5):660-668.
Score: 0.003
-
Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. J Urol. 2017 09; 198(3):530-537.
Score: 0.003
-
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515.
Score: 0.003
-
Effect of Mammography on Marker Clip Migration After Stereotactic-Guided Core Needle Breast Biopsy. Curr Probl Diagn Radiol. 2017 Nov - Dec; 46(6):410-414.
Score: 0.003
-
Imaging-Concordant Benign MRI-Guided Vacuum-Assisted Breast Biopsy May Not Warrant MRI Follow-Up. AJR Am J Roentgenol. 2017 Apr; 208(4):916-922.
Score: 0.003
-
Use of Spinal Cord Diffusion Tensor Imaging to Quantify Neural Ablation and Evaluate Outcome after Percutaneous Cordotomy for Intractable Cancer Pain. Stereotact Funct Neurosurg. 2017; 95(1):34-39.
Score: 0.003
-
Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget. 2016 Dec 27; 7(52):86280-86289.
Score: 0.003
-
Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study. Cancer. 2017 04 01; 123(7):1115-1123.
Score: 0.003
-
Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual. Clin Cancer Res. 2017 Mar 15; 23(6):1407-1413.
Score: 0.003
-
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 2016 10 25; 14(1):168.
Score: 0.003
-
Outcomes of patients =65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER. Int J Cancer. 2017 Jan 01; 140(1):208-215.
Score: 0.003
-
Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Sci Rep. 2016 10 17; 6:35448.
Score: 0.003
-
Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget. 2016 Sep 27; 7(39):64421-64430.
Score: 0.003
-
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res. 2017 Mar 15; 23(6):1388-1396.
Score: 0.003
-
Survival after radiosurgery for brain metastasis: regarding Buatti et al. IJROBP 32(4):1161-1166; 1995. Int J Radiat Oncol Biol Phys. 1996 Sep 01; 36(2):523.
Score: 0.003
-
Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. Clin Cancer Res. 2016 Sep 01; 22(17):4291-301.
Score: 0.003
-
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemother Pharmacol. 2016 07; 78(1):167-71.
Score: 0.003
-
Incidental Suspicious Regional Lymph Nodes on Breast Sonography: Is Sampling Necessary? Curr Probl Diagn Radiol. 2017 Mar - Apr; 46(2):100-104.
Score: 0.003
-
Critical Assessment of Clinical Prognostic Tools in Melanoma. Ann Surg Oncol. 2016 09; 23(9):2753-61.
Score: 0.003
-
Are time or intensity factors important to the definition of metastases of unknown origin? J Natl Cancer Inst. 1996 Apr 03; 88(7):462-3.
Score: 0.003
-
Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer. 2016 06 15; 122(12):1836-43.
Score: 0.003
-
Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells. J Transl Med. 2016 Feb 09; 14:46.
Score: 0.003
-
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2016 Mar 20; 34(9):945-52.
Score: 0.003
-
American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. CA Cancer J Clin. 2016 09; 66(5):370-4.
Score: 0.003
-
Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget. 2015 Sep 29; 6(29):28453-62.
Score: 0.003
-
Development of a model to predict breast cancer survival using data from the National Cancer Data Base. Surgery. 2016 Feb; 159(2):495-502.
Score: 0.003
-
Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med. 1995 Aug 15; 14(15):1707-23.
Score: 0.003
-
Reproducibility of Variant Calls in Replicate Next Generation Sequencing Experiments. PLoS One. 2015; 10(7):e0119230.
Score: 0.003
-
The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab. Oncologist. 2015 Jul; 20(7):737-41.
Score: 0.003
-
Role of Ultrasonography of Regional Nodal Basins in Staging Triple-Negative Breast Cancer and Implications For Local-Regional Treatment. Int J Radiat Oncol Biol Phys. 2015 Sep 01; 93(1):102-10.
Score: 0.003
-
Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol. 2015 Jun; 16(6):695-703.
Score: 0.003
-
Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard? J Neurooncol. 2015 May; 123(1):141-50.
Score: 0.003
-
Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. Oncologist. 2015 May; 20(5):466-73.
Score: 0.003
-
Prognostic factors and patterns of relapse in ewing sarcoma patients treated with chemotherapy and r0 resection. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):349-57.
Score: 0.003
-
Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines. Support Care Cancer. 2015 Sep; 23(9):2649-54.
Score: 0.003
-
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol. 2015 May; 26(5):1012-1018.
Score: 0.003
-
Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget. 2014 Oct 15; 5(19):8937-46.
Score: 0.002
-
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol. 2015 Feb; 17(2):266-73.
Score: 0.002
-
MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. Clin Genitourin Cancer. 2015 Feb; 13(1):e19-26.
Score: 0.002
-
Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nat Biotechnol. 2014 Jul; 32(7):644-52.
Score: 0.002
-
Characteristics and survival of patients with advanced cancer and p53 mutations. Oncotarget. 2014 Jun 15; 5(11):3871-9.
Score: 0.002
-
Assessing time-by-covariate interactions in proportional hazards regression models using cubic spline functions. Stat Med. 1994 May 30; 13(10):1045-62.
Score: 0.002
-
Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy. Invest New Drugs. 2014 Aug; 32(4):717-22.
Score: 0.002
-
Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer. 2014 Jul 01; 120(13):1932-8.
Score: 0.002
-
Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. Oncologist. 2014 Apr; 19(4):426-8.
Score: 0.002
-
Implications of bevacizumab discontinuation in adults with recurrent glioblastoma. Neuro Oncol. 2014 Jun; 16(6):823-8.
Score: 0.002
-
Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab. Oncologist. 2014 Mar; 19(3):228-34.
Score: 0.002
-
The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials. Ann Oncol. 2014 Jan; 25(1):276-82.
Score: 0.002
-
IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol. 2014 Jan; 16(1):81-91.
Score: 0.002
-
Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs. Clin Cancer Res. 2014 Jan 15; 20(2):281-8.
Score: 0.002
-
Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients. Cancer. 1993 Oct 01; 72(7):2291-2.
Score: 0.002
-
Human endogenous retrovirus type K antibodies and mRNA as serum biomarkers of early-stage breast cancer. Int J Cancer. 2014 Feb 01; 134(3):587-95.
Score: 0.002
-
Abdominal aortic aneurysm measurement: a critique of methods for comparison studies. Invest Radiol. 1993 Aug; 28(8):787-8.
Score: 0.002
-
The prognostic impact of age in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2013 Apr; 138(2):591-9.
Score: 0.002
-
A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases. Cancer Chemother Pharmacol. 2013 Apr; 71(4):955-63.
Score: 0.002
-
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 2013 Jan; 4(1):156-65.
Score: 0.002
-
Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat. 2013 Jan; 137(2):631-6.
Score: 0.002
-
Phospho-histone H3 (pHH3) immuno-reactivity as a prognostic marker in non-functioning pituitary adenomas. Pituitary. 2012 Dec; 15(4):556-61.
Score: 0.002
-
Report of the 2011 University of Puerto Rico-MD Anderson Cancer Center conference entitled "Population-Based Studies in Hispanics: Methodological Issues in Cancer Research". P R Health Sci J. 2012 Mar; 31(1):39-41.
Score: 0.002
-
Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer. 2012 Jul 15; 118(14):3599-606.
Score: 0.002
-
EFEMP1 suppresses malignant glioma growth and exerts its action within the tumor extracellular compartment. Mol Cancer. 2011 Sep 28; 10:123.
Score: 0.002
-
Systematic analysis of in vitro chemosensitivity and mib-1 expression in molecular breast cancer subtypes. Eur J Cancer. 2012 Sep; 48(13):2066-74.
Score: 0.002
-
Confidence intervals and survival estimates. J Thorac Cardiovasc Surg. 1991 Sep; 102(3):456-9.
Score: 0.002
-
Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer. Cancer Epidemiol. 2012 Apr; 36(2):206-11.
Score: 0.002
-
DNA mismatch repair network gene polymorphism as a susceptibility factor for pancreatic cancer. Mol Carcinog. 2012 Jun; 51(6):491-9.
Score: 0.002
-
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 2011 Jun 15; 13(3):R67.
Score: 0.002
-
Glucose metabolism gene variants modulate the risk of pancreatic cancer. Cancer Prev Res (Phila). 2011 May; 4(5):758-66.
Score: 0.002
-
Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold? Ann Oncol. 2011 Nov; 22(11):2387-2393.
Score: 0.002
-
DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer. Oncologist. 2011; 16(1):61-70.
Score: 0.002
-
Glucose metabolism gene polymorphisms and clinical outcome in pancreatic cancer. Cancer. 2011 Feb 01; 117(3):480-91.
Score: 0.002
-
Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res. 2010 Nov 01; 16(21):5351-61.
Score: 0.002
-
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol. 2010 Aug; 28(8):827-38.
Score: 0.002
-
Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. Mol Cancer Ther. 2010 May; 9(5):1120-7.
Score: 0.002
-
Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer. Gastroenterology. 2010 Aug; 139(2):464-73, 473.e1-3.
Score: 0.002
-
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs. 2011 Aug; 29(4):694-9.
Score: 0.002
-
Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res. 2010; 12(1):R5.
Score: 0.002
-
Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro. Mol Cancer. 2009 Nov 10; 8:99.
Score: 0.002
-
Abdominal aortic aneurysm. N Engl J Med. 1989 Oct 12; 321(15):1040-2.
Score: 0.002
-
Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009 Nov; 10(11):1037-44.
Score: 0.002
-
Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol. 2009 Sep; 94(2):229-34.
Score: 0.002
-
Prediction of left ventricular ejection fraction using a unique method of chest x-ray and ECG analysis: a noninvasive index of cardiac performance based on the concept of heart volume and mass interrelationship. Am Heart J. 1989 Mar; 117(3):590-8.
Score: 0.002
-
Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat. 2010 Jan; 119(2):305-14.
Score: 0.002
-
Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. J Clin Oncol. 2009 Apr 01; 27(10):1592-9.
Score: 0.002
-
Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer. 2008 Oct 15; 113(8):2046-52.
Score: 0.002
-
Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol. 2008 Sep 20; 26(27):4442-8.
Score: 0.002
-
Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. Neuro Oncol. 2008 Dec; 10(6):1010-8.
Score: 0.002
-
Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer. J Clin Oncol. 2008 Oct 01; 26(28):4679-83.
Score: 0.002
-
Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol. 2008 Oct; 90(1):89-97.
Score: 0.002
-
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008 Mar 10; 26(8):1316-23.
Score: 0.002
-
A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol. 2008 Apr; 10(2):208-15.
Score: 0.002
-
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol. 2008 Apr; 10(2):216-22.
Score: 0.002
-
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008 Mar 10; 26(8):1275-81.
Score: 0.002
-
Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res. 2007 Dec 15; 13(24):7401-6.
Score: 0.002
-
Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer. Cancer. 2007 Nov 15; 110(10):2186-90.
Score: 0.002
-
Phosphorylated Pak1 level in the cytoplasm correlates with shorter survival time in patients with glioblastoma. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6603-9.
Score: 0.002
-
Activation of polyamine catabolism by N1,N11-diethylnorspermine leads to cell death in glioblastoma. Int J Oncol. 2007 Aug; 31(2):431-40.
Score: 0.002
-
CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma. AJR Am J Roentgenol. 2007 Aug; 189(2):378-85.
Score: 0.002
-
Telomere 3' overhang-specific DNA oligonucleotides induce autophagy in malignant glioma cells. FASEB J. 2007 Sep; 21(11):2918-30.
Score: 0.001
-
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol. 2007 Mar; 8(3):203-11.
Score: 0.001
-
Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007 Jan 01; 13(1):234-40.
Score: 0.001
-
Outcome of gastric cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival. Cancer. 2006 Dec 01; 107(11):2576-80.
Score: 0.001
-
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol. 2007 Feb; 81(3):271-7.
Score: 0.001
-
Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol. 2006 Sep 01; 24(25):4107-15.
Score: 0.001
-
Complementary and alternative medicine use and quality of life in patients with primary brain tumors. J Pain Symptom Manage. 2006 Aug; 32(2):148-54.
Score: 0.001
-
Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst. 2006 May 03; 98(9):625-36.
Score: 0.001
-
Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. J Neurooncol. 2006 Oct; 80(1):83-90.
Score: 0.001
-
Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation. J Clin Oncol. 2006 Apr 01; 24(10):1627-32.
Score: 0.001
-
Reproducibility of gene expression signature-based predictions in replicate experiments. Clin Cancer Res. 2006 Mar 15; 12(6):1721-7.
Score: 0.001
-
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2006 Apr; 8(2):189-93.
Score: 0.001
-
Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol. 2006 Apr 10; 24(11):1720-8.
Score: 0.001
-
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol. 2005 Nov 20; 23(33):8331-9.
Score: 0.001
-
The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer. 2005 Oct 01; 104(7):1468-77.
Score: 0.001
-
Modeling prognosis for patients with malignant astrocytic gliomas: quantifying the expression of multiple genetic markers and clinical variables. Neuro Oncol. 2005 Oct; 7(4):485-94.
Score: 0.001
-
Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005 Aug 15; 11(16):5678-85.
Score: 0.001
-
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005 Aug; 23(4):357-61.
Score: 0.001
-
Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips. J Mol Diagn. 2005 Aug; 7(3):357-67.
Score: 0.001
-
Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. Cancer. 2005 Jun 15; 103(12):2485-90.
Score: 0.001
-
Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A. 2005 Jun 07; 102(23):8315-20.
Score: 0.001
-
Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol. 2005 May 01; 23(13):3094-103.
Score: 0.001
-
PAX6 suppresses growth of human glioblastoma cells. J Neurooncol. 2005 Feb; 71(3):223-9.
Score: 0.001
-
Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):440-9.
Score: 0.001
-
Mechanisms of action of rapamycin in gliomas. Neuro Oncol. 2005 Jan; 7(1):1-11.
Score: 0.001
-
Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs. 2004 Nov; 22(4):427-35.
Score: 0.001
-
A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest New Drugs. 2004 Nov; 22(4):459-66.
Score: 0.001
-
Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol. 2004 Nov 01; 22(21):4282-9.
Score: 0.001
-
Overexpression of synuclein-gamma in pancreatic adenocarcinoma. Cancer. 2004 Jul 01; 101(1):58-65.
Score: 0.001
-
13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme. Neuro Oncol. 2004 Jul; 6(3):253-8.
Score: 0.001
-
Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004 Jun; 239(6):818-25; discussion 825-7.
Score: 0.001
-
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004 Jun 15; 22(12):2284-93.
Score: 0.001
-
Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. Cancer. 2004 Apr 15; 100(8):1712-6.
Score: 0.001
-
Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer. 1994 Mar 01; 73(5):1533-5.
Score: 0.001
-
Identification of necrosis-associated genes in glioblastoma by cDNA microarray analysis. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):212-21.
Score: 0.001
-
O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas. Neuro Oncol. 2004 Jan; 6(1):28-32.
Score: 0.001
-
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. Neuro Oncol. 2004 Jan; 6(1):33-7.
Score: 0.001
-
Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2004 Jan; 6(1):44-54.
Score: 0.001
-
The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res. 2003 Aug 15; 9(9):3369-75.
Score: 0.001
-
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res. 2003 Jul; 9(7):2406-15.
Score: 0.001
-
Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer. 2003 Jun 15; 97(12):2960-71.
Score: 0.001
-
Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2003 Jun 15; 21(12):2305-11.
Score: 0.001
-
Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response. Clin Cancer Res. 2003 Mar; 9(3):955-60.
Score: 0.001
-
Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res. 2003 Mar; 9(3):981-90.
Score: 0.001
-
Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival. Oncology. 2003; 65(3):259-66.
Score: 0.001
-
Identification of combination gene sets for glioma classification. Mol Cancer Ther. 2002 Nov; 1(13):1229-36.
Score: 0.001
-
Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J. 2002 Nov-Dec; 8(6):461-8.
Score: 0.001
-
Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2002 Sep 15; 20(18):3792-803.
Score: 0.001
-
Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol. 2002 Sep 15; 20(18):3804-14.
Score: 0.001
-
Treatment outcomes of resected esophageal cancer. Ann Surg. 2002 Sep; 236(3):376-84; discussion 384-5.
Score: 0.001
-
Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer. 2002 Sep 01; 95(5):1120-6.
Score: 0.001
-
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys. 2002 May 01; 53(1):58-66.
Score: 0.001
-
A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study. Neuro Oncol. 2002 Apr; 4(2):109-14.
Score: 0.001
-
Tumor specific gene expression profiles in human leiomyosarcoma: an evaluation of intratumor heterogeneity. Cancer. 2002 Apr 01; 94(7):2069-75.
Score: 0.001
-
Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol. 2002 Mar 01; 20(5):1383-8.
Score: 0.001
-
Spinal cord protection during aortic cross clamping: retrograde venous spinal cord perfusion, distal aortic perfusion, and cerebrospinal fluid drainage. Scand Cardiovasc J. 2002 Feb; 36(1):6-10.
Score: 0.001
-
Expression of metastasis-related genes in human epithelial ovarian tumors. Int J Oncol. 2002 Jan; 20(1):5-13.
Score: 0.001
-
Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets. Brain Pathol. 2002 Jan; 12(1):108-16.
Score: 0.001
-
CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980. Cancer Invest. 2002; 20(7-8):948-54.
Score: 0.001
-
Effects of sex and racial/ethnic group on the pattern of gastric cancer localization. Gastric Cancer. 2002; 5(4):208-12.
Score: 0.001
-
A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001 Aug; 95(2):190-8.
Score: 0.001
-
Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients. Ann Surg. 2001 Jul; 234(1):47-55.
Score: 0.001
-
Survival and recurrence factors in adult medulloblastoma: the M.D. Anderson Cancer Center experience from 1978 to 1998. Neuro Oncol. 2001 07; 3(3):167-73.
Score: 0.001
-
Surgery for abdominal metastases of cutaneous melanoma. World J Surg. 2001 Jun; 25(6):750-8.
Score: 0.001
-
Phase I bioequivalency study of MitoExtra and mitomycin C in patients with solid tumors. Cancer. 2001 Feb 15; 91(4):815-21.
Score: 0.001
-
Identifying differentially expressed genes in cDNA microarray experiments. J Comput Biol. 2001; 8(6):639-59.
Score: 0.001
-
Patterns of expression of Rb and p16 in astrocytic gliomas, and correlation with survival. Int J Oncol. 2000 Nov; 17(5):963-9.
Score: 0.001
-
Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas. J Clin Oncol. 2000 Oct 01; 18(19):3378-83.
Score: 0.001
-
Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol. 2000 Feb; 18(3):646-50.
Score: 0.001
-
Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res. 1999 Sep 01; 59(17):4228-32.
Score: 0.001
-
A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1999 Aug 01; 45(1):127-35.
Score: 0.001
-
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999 Aug; 17(8):2572-8.
Score: 0.001
-
Prognostic factors in resectable pancreatic cancer: p53 and bcl-2. J Gastrointest Surg. 1999 May-Jun; 3(3):263-77.
Score: 0.001
-
Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res. 1999 Apr 15; 59(8):1820-4.
Score: 0.001
-
Gamma-ray mutagen sensitivity and survival in patients with glioma. Clin Cancer Res. 1998 Dec; 4(12):3031-5.
Score: 0.001
-
Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance. Clin Cancer Res. 1998 Oct; 4(10):2447-54.
Score: 0.001
-
Ependymomas: MIB-1 proliferation index and survival. J Neurooncol. 1998 Oct; 40(1):51-7.
Score: 0.001
-
Cancer among a Michigan cohort exposed to polybrominated biphenyls in 1973. Epidemiology. 1998 Jul; 9(4):373-8.
Score: 0.001
-
Reduction of neurologic injury after high-risk thoracoabdominal aortic operation. Ann Thorac Surg. 1998 Jul; 66(1):132-8.
Score: 0.001
-
Unknown primary tumors metastatic to liver. J Clin Oncol. 1998 Jun; 16(6):2105-12.
Score: 0.001
-
Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery. 1998 May; 42(5):1044-55; discussion 1055-6.
Score: 0.001
-
Correlation between dynamic MRI and outcome in patients with malignant gliomas. Neurology. 1998 Mar; 50(3):777-81.
Score: 0.001
-
p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer. Clin Cancer Res. 1997 Oct; 3(10):1685-90.
Score: 0.001
-
Screening for colorectal cancer. A comparison of 3 fecal occult blood tests. Arch Intern Med. 1997 May 12; 157(9):970-6.
Score: 0.001
-
Pelvic exenteration for locally advanced rectal carcinoma: factors predicting improved survival. Surgery. 1997 May; 121(5):479-87.
Score: 0.001
-
Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma? J Clin Oncol. 1997 May; 15(5):2056-66.
Score: 0.001
-
Evaluation of sister chromatid exchange and chromosome breaks in a cohort of untreated Hodgkin's disease patients. Cancer Epidemiol Biomarkers Prev. 1997 Apr; 6(4):291-3.
Score: 0.001
-
TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol. 1997 Mar; 15(3):1063-70.
Score: 0.001
-
Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor. Clin Cancer Res. 1996 Sep; 2(9):1489-97.
Score: 0.001
-
Surgery versus radiosurgery in the treatment of brain metastasis. J Neurosurg. 1996 May; 84(5):748-54.
Score: 0.001
-
Prognostic significance of p53 immunoreactivity in patients with glioma. Clin Cancer Res. 1995 Dec; 1(12):1617-22.
Score: 0.001
-
Reoperation for recurrent metastatic brain tumors. J Neurosurg. 1995 Oct; 83(4):600-4.
Score: 0.001
-
Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol. 1995 Aug; 13(8):2094-103.
Score: 0.001
-
Aggressive meningeal tumors: review of a series. J Neurosurg. 1995 Jan; 82(1):17-27.
Score: 0.001
-
Influence of segmental arteries, extent, and atriofemoral bypass on postoperative paraplegia after thoracoabdominal aortic operations. J Vasc Surg. 1994 Aug; 20(2):255-62.
Score: 0.001
-
Effect of pregnancy on prognosis for young women with breast cancer. Lancet. 1994 Jun 25; 343(8913):1587-9.
Score: 0.001
-
Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol. 1994 Jun; 12(6):1272-80.
Score: 0.001
-
Primary adenocarcinoma of the duodenum: management and survival in 67 patients. Ann Surg Oncol. 1994 Jan; 1(1):73-8.
Score: 0.001
-
Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer. 1993 May 15; 71(10):3119-23.
Score: 0.001
-
Percutaneous transluminal coronary angioplasty utilizing prolonged balloon inflations: initial results and six-month follow-up. Cathet Cardiovasc Diagn. 1991 Aug; 23(4):239-44.
Score: 0.000
-
Pacemaker follow-up: its role in the detection and correction of pacemaker system malfunction. Pacing Clin Electrophysiol. 1986 May; 9(3):387-91.
Score: 0.000
-
Thoracoabdominal aortic aneurysms: preoperative and intraoperative factors determining immediate and long-term results of operations in 605 patients. J Vasc Surg. 1986 Mar; 3(3):389-404.
Score: 0.000